EHS
EHS

Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization | BMC Gastroenterology


  • Globocan. International agency for research on cancer 2020 (Available from: https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf).

  • Bolondi L, Burroughs A, Dufour J-F, Galle PR, Mazzaferro V, Piscaglia F, et al., editors. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Seminars in liver disease; 2012: Thieme Medical Publishers.

  • Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD Guidelines Treatment Hepatocell Carcinoma. 2018;67(1):358–80.


    Google Scholar
     

  • EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.

  • Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.

    Article 

    Google Scholar
     

  • Kudo M, Han KH, Ye SL, Zhou J, Huang YH, Lin SM, et al. A Changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific primary liver cancer expert consensus statements. Liver Cancer. 2020;9(3):245–60.

    CAS 
    Article 

    Google Scholar
     

  • Miksad RA, Ogasawara S, Xia F, Fellous M. Piscaglia FJBc. Liver Funct Change Trans Chemoembolization US Hepatocellular Carcinoma Patient: Livert Study. 2019;19(1):1–8.

    CAS 

    Google Scholar
     

  • Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, et al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32(4):348–59.

    CAS 
    PubMed 

    Google Scholar
     

  • European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56(4):908–43.

  • Durand F, Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis. 2008;28(1):110–22.

    CAS 
    Article 

    Google Scholar
     

  • Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. J Clinic Oncol. 2015;33(6):550.

    Article 

    Google Scholar
     

  • Kim JH, Sinn DH, Lee J-H, Hyun D, Cho SK, Shin SW, et al. Novel albumin–bilirubin grade-based risk prediction model for patients with hepatocellular carcinoma undergoing chemoembolization. Digestive Diseases Sci. 2018;63(4):1062–71.

    CAS 
    Article 

    Google Scholar
     

  • Lee IC, Hung YW, Liu CA, Lee RC, Su CW, Huo TI, et al. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. Liver Internat. 2019;39(9):1704–12.

    CAS 
    Article 

    Google Scholar
     

  • Chi C-T, Lee I, Lee R-C, Hung Y-W, Su C-W, Hou M-C, et al. Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection. Cancer. 2021;13(17):4325.

    Article 

    Google Scholar
     

  • Kariyama K, Nouso K, Hiraoka A, Wakuta A, Oonishi A, Kuzuya T, et al. EZ-ALBI Score for predicting hepatocellular carcinoma prognosis. Liver Cancer. 2020;9(6):734–43.

    CAS 
    Article 

    Google Scholar
     

  • Ho SY, Liu PH, Hsu CY, Ko CC, Huang YH, Su CW, et al. EZ-ALBI score as a new prognostic predictor in hepatocellular carcinoma. Hepatol Res. 2021;51(11):1129.

    CAS 
    Article 

    Google Scholar
     

  • Sangro B, Salem R. Transarterial chemoembolization and radioembolization. Semin Liver Dis. 2014;34(4):435–43.

    Article 

    Google Scholar
     

  • Ho S-Y, Liu P-H, Hsu C-Y, Hsia C-Y, Lee Y-H, Lee R-C, et al. Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. PLoS ONE. 2017;12(7): e0180408.

    Article 

    Google Scholar
     

  • Park Y, Kim BK, Park JY, Kim DY, Ahn SH, Han K-H, et al. Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma. BMC Cancer. 2019;19(1):1–10.

    Article 

    Google Scholar
     

  • Kohla MA, Zeid MIA, Al-Warraky M, Taha H. Predictors of hepatic decompensation after TACE for hepatocellular carcinoma. BMJ Open Gastroenterol. 2015;2(1): e000032.

    Article 

    Google Scholar
     

  • Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JFHJH. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatol. 2016;64(1):106–16.

    CAS 
    Article 

    Google Scholar
     

  • Li J-X, Wu H, Huang J-W. Zeng YJJotFMA The influence on liver function after transcatheter arterial chemoembolization combined with percutaneous radiofrequency ablation in patients with hepatocellular carcinoma. J Formosan Med Assoc. 2012;111(9):510–5.

    Article 

    Google Scholar
     

  • Kudo M, Raoul J-L, Lee HC, Cheng A-L, Nakajima K, Peck-Radosavljevic M. Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): An exploratory analysis of OPTIMIS—An international observational study assessing the use of sorafenib after TACE. Am Soc Clinic Oncol. 2018;36(4):368.

    Article 

    Google Scholar
     

  • Peng Y, Qi X, Guo XJM. Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Medicine. 2016;95(8):58.

    Article 

    Google Scholar
     

  • Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, et al. Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function. Liver Cancer. 2017;6(4):325–36.

    CAS 
    Article 

    Google Scholar
     

  • Hiraoka A, Kumada T, Kudo M, Hirooka M, Tsuji K, Itobayashi E, et al. Albumin-bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: a comparison with the liver damage and Child-Pugh classifications. Liver Cancer. 2017;6(3):204–15.

    Article 

    Google Scholar
     

  • Hsu W-F, Chang K-C, Chen T-H, Lin C-H, Lin Y-C, Tsai M-H, et al. Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma. Medicine. 2021;100(33):e2700.

    Article 

    Google Scholar
     

  • Akarapatima K, Chang A, Prateepchaiboon T, et al. Predictive outcomes using child-turcotte-pugh and albumin-bilirubin scores in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Gastrointest Cancer. 2021:1–8.

  • Vogeler M, Mohr I, Pfeiffenberger J, Sprengel SD, Klauss M, Teufel A, et al. Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. J Cancer Res Clinic Oncol. 2020;146(4):1033–50.

    CAS 
    Article 

    Google Scholar
     

  • Brar G, Greten TF, Graubard BI, McNeel TS, Petrick JL, McGlynn KA, et al. Hepatocellular carcinoma survival by etiology: A SEER-medicare database analysis. Hepatol Commun. 2020;4(10):1541–51.

    Article 

    Google Scholar
     



  • Source link

    EHS
    Back to top button